[Translation] A multicenter, multicenter, safety lead-in component to study the efficacy, safety, and pharmacokinetics of encorafenib in combination with binimetinib in BRAF inhibitor- and MEK inhibitor-naïve Chinese patients with BRAF V600E-mutated metastatic non-small cell lung cancer , open-label, phase II study
探讨Encorafenib联合Binimetinib治疗中国BRAF V600E突变型NSCLC患者的临床疗效、安全性及PK。由于Encorafenib联合Binimetinib尚未在中国患者中进行评估,因此本研究包括一项安全性导入(Safety Lead-In,SLI)评估9例患者中的Encorafenib联合Binimetinib的安全性和耐受性。
[Translation] To investigate the clinical efficacy, safety and PK of Encorafenib combined with Binimetinib in the treatment of Chinese patients with BRAF V600E mutant NSCLC. Since Encorafenib in combination with Binimetinib has not been evaluated in Chinese patients, this study included a Safety Lead-In (SLI) to evaluate the safety and tolerability of Encorafenib in combination with Binimetinib in 9 patients.